Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 3, 2013, Pages 361-367

  Luzze, H ^a   Johnson, D F ^b   Dickman, K ^b   Mayanja Kizza, H ^c   Okwera, A ^a   Eisenach, K ^d   Cave, M D ^e   Whalen, C C ^f   Johnson, J L ^b   Boom, W H ^b   Joloba, M ^c  

^a MULAGO HOSPITAL   (Uganda)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

Author keywords

HIV; Retreatment; RFLP

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SURVEILLANCE; DRUG EFFECT; ENDEMIC DISEASE; FEMALE; FOLLOW UP; GENE INSERTION SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYCOBACTERIUM TUBERCULOSIS; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RECURRENT INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; TUBERCULOSIS; UGANDA; URBAN AREA;

ADULT; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANTITUBERCULAR AGENTS; COINFECTION; ENDEMIC DISEASES; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RIFAMPIN; RISK ASSESSMENT; RISK FACTORS; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; UGANDA; URBAN HEALTH;

EID: 84874102420     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0692     Document Type: Article

References (35)

1. Dobler C C, Marks G B, Simpson S E, Hamish Crawford A B. Recurrence of tuberculosis at a Sydney chest clinic between 1994 and 2006: reactivation or reinfection? Med J Aust 2008; 188: 153-155.
2. Van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
3. Jasmer R M, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-1366.
4. Caminero J A, Pena M J, Campos-Herrero M I, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163(3 Pt 1): 717-720.
5. Garcia de Viedma D, Marin M, Hernangomez S, et al. Tuberculosis recurrences: reinfection plays a role in a population whose clinical/ epidemiological characteristics do not favor reinfection. Arch Intern Med 2002; 162: 1873-1879.
6. Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
7. Verver S, Warren R, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171: 1430-1435.
8. Wang J Y, Lee L, Lai H, et al. Prediction of the tuberculosis reinfection proportion from the local incidence. J Infect Dis 2007; 196: 281-288.
9. Charalambous S, Grant A D, Moloi V, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2008; 12: 942-948.
10. Crampin A C, Mwaungulu J M, Mwaungulu F D, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24: 417-426.
11. World Health Organization. Global tuberculosis control 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
12. Guwatudde D, Zalwango S, Kamya M R, et al. Burden of tuberculosis in Kampala, Uganda. Bull World Health Organ 2003; 81: 799-805.
13. Joint United Nations Programme on HIV/AIDS 2010. Uganda HIV and AIDS estimates 2009. Geneva, Switzerland: UNAID, 2010.
14. Johnson J L, Okwera A, Nsubuga P, et al. Efficacy of an unsu-pervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Int J Tuberc Lung Dis 2000; 4: 1032-1040.
15. Fitzpatrick L K, Okwera A, Mugerwa R, Ridzon R, Ellner J, Onorato I. An investigation of suspected exogenous reinfection in tuberculosis patients in Kampala, Uganda. Int J Tuberc Lung Dis 2002; 6: 550-552.
16. Okwera A, Johnson J L, Luzze H, et al. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis 2006; 10: 39-44.
17. Johnson J L, Kamya R M, Okwera A, et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in nonhuman immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis 2000; 181: 1304-1312.
18. Johnson J L, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 185-191.
19. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immuno-adjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191: 856-865.
20. Whalen C C, Chiunda A, Zalwango S, Nshuti L, Jones-Lopez E. Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. Am J Trop Med Hyg 2006; 75: 55-61.
21. Johnson J L, Hadad D J, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180: 558-563.
22. Nanteza M W, Mayanja-Kizza H, Charlebois E, et al. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4+ T-cell counts of ≥350 cells/μl. J Infect Dis 2011; 204: 884-892.
23. BD. BBL MGIT products for the detection of mycobacteria. Cockeysville, MD, USA: BD Microbiology Systems, 1994.
24. Otal I, Samper S, Asensio M P, et al. Use of a PCR method based on IS6110 polymorphism for typing Mycobacterium tuberculosis strains from BACTEC cultures. J Clin Micro 1997; 35: 273-277.
25. van Embden J D, Cave M D, Crawford J T, et al. Strain identi-fication of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-409.
26. Behr M A, Small P M. Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? Clin Infect Dis 1997; 25: 806-810.
27. Falk A, O'Connor J B, Pratt P C, Webb W R, Wier J A, Wolinsky E. Chapter 6. Classification of pulmonary tuberculosis. In: Diagnostic standards and classification of tuberculosis. 12th ed. New York, NY, USA: National Tuberculosis and Respiratory Disease Association, 1969: pp 68-76.
28. Panjabi R, Comstock G W, Golub J E. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007; 11: 828-837.
29. Joloba M L, Whalen C C, Cave D M, et al. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda. East Afr Med J 2000; 77: 111-115.
30. Godfrey-Faussett P, Githui W, Barchelor B, et al. Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. Tubercle Lung Dis 1994; 75: 199-202.
31. Nunn A J, Phillips P P J, Mitchison D A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010; 14: 241-242.
32. Ormerod L P, Prescott R J. Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis. Respir Med 1991; 85: 239-242.
33. Dickman K R, Nabyonga L, Kateet D D, et al. Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. BMC Infect Dis 2010; 10: 349.
34. Pulido F, Pena J, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157: 227-232.
35. Chang K C, Leung C C, Yew W W, Ho S C, Tam C M. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170: 1124-1130.